Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC



Hepatocellular carcinoma (HCC) is one of the most common cancer-related causes of death worldwide and there is a clear need for further treatment options. In this study, we assessed the efficacy of a combination of lentinan (a fungal extract), transcatheter arterial chemoembolisation (TACE) and radiofrequency ablation (RFA) in HCC patients.


Seventy-eight patients with HCC confirmed by pathology and iconographical checks were used in this study. A total of 136 tumours with a mean diameter of 6.5 cm were detected (standard deviation [SD]±0.7). Subjects were divided into four groups, receiving either TACE only, RFA only, RFA and TACE, or the combination group — receiving lentinan, RFA and TACE.


The tumour necrosis was significantly higher in the combination group (88.6%), compared to the TACE group (37.5%), the RFA group (47.8%) and the TACE/RFA group (60.3%; P<0.05). The tumour recurrence rate was significantly lower in the combination group (17.8%), compared to the TACE group (45.8%), the RFA group (34.7%) and the TACE/RFA group (29.0%; P<0.05). Finally, mean survival duration was significantly higher in the combination group (28.2 months; P<0.05).


Combination therapy involving lentinan, RFA and TACE was beneficial in terms of increasing mean survival duration, tumour necrosis and reducing the recurrence rate. Lentinan may therefore be of benefit to HCC patients.


  1. 1.

    Höpfner M, Huether A, Sutter A, Baradari V, Schuppan D, Scherübl H. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol. 2006;71:1435–1448.

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Cormier JN, Thomas KT, Chari RS, Pinson CW. Management of hepatocellular carcinoma. J Gastrointest Surg. 2006;10:761–780.

    PubMed  Article  Google Scholar 

  3. 3.

    Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 2003;52:1–8.

    Article  Google Scholar 

  4. 4.

    McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091–1096.

    PubMed  CAS  Google Scholar 

  5. 5.

    Lee CM, Lu SN, Changchien CS, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer. 1999;86:1143–1150.

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med. 1994;120:302–309.

    PubMed  CAS  Google Scholar 

  7. 7.

    Baere T, Dufaux J, Roche A, et al. Circulatory alterations induced by intraarterial injection of iodized oil and emulsions of iodized oil and doxorubicin: experimental study. Radiology. 1995;194:165–170.

    PubMed  CAS  Google Scholar 

  8. 8.

    De Mitri MS, Puossin K, Baccarini P, et al. HCV-associated liver cancer without cirrhosis. Lancet. 1995;345:413–415.

    PubMed  Article  Google Scholar 

  9. 9.

    Liapi E, Geschwind JFH. Transcatheter arterial chemoembolisation (TACE) for HCC’ classic concepts and future evolution. Eur Oncological Dis. 2006;1:47–52.

    Google Scholar 

  10. 10.

    Tsukuma H, Hiyami T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797–1801.

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Frazer C. Imaging of hepatocellular carcinoma. J Gastroenterol Hepatol. 1999;14:750–756.

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Sugimori K, Nozawa A, Morimoto M, et al. Extension of radiofrequency ablation of the liver by transcatheter arterial embolization with iodized oil and gelatin sponge: results in a pig model. J Vasc Interv Radiol. 2005;16:849–856.

    PubMed  Google Scholar 

  13. 13.

    Dominguez S, Denys A, Madeira I, et al. Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumors. Eur J Gastroenterol Hepatol. 2000;12:151–157.

    PubMed  CAS  Article  Google Scholar 

  14. 14.

    Casadei R, Tomassetti P, Rossi C, la Donna M, Migliori M, Marrano D. Treatment of metastatic glucagonoma to the liver: case report and literature review. Ital J Gastroenterol Hepatol. 1999;31:308–312.

    PubMed  CAS  Google Scholar 

  15. 15.

    Bizollon T, Rode A, Bancel B, et al. Diagnostic value and tolerance of lipiodolcomputed tomography for the detection of small hepatocellular carcinoma: correlation with pathologic examination of explanted livers. J Hepatol. 1998;28:491–496.

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Wu P, Zhang F, Zhao M, et al. Combination of transcatheter arterial chemoembolization and CT-guided radiofrequency ablation in treating advanced hepatocellular carcinoma. Chin J Radiology (Chin). 2003;37:901–904.

    Google Scholar 

  17. 17.

    Zhang L, Cui Z, Zhao Q, et al. RFA combined with TACE and ethanol injection for unresectable hepatic carcinoma. Chin J General Surg (Chin). 2002;40:826–829.

    Google Scholar 

  18. 18.

    Lindequist U, Niedermeyer TH, Jülich WD. The pharmacological potential of mushrooms. eCAM. 2005;2:285–299.

    PubMed  Google Scholar 

  19. 19.

    Wasser SP, Weis AL. Medicinal properties of substances occurring in higher basidiomycetes mushrooms: current perspectives (review). Int J Med Mushrooms. 1999;1:31–62.

    CAS  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Baozhong Shen.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yang, P., Liang, M., Zhang, Y. et al. Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Adv Therapy 25, 787 (2008).

Download citation


  • hepatocellular carcinoma
  • lentinan
  • radiofrequency ablation
  • transcatheter hepatic arterial chemoembolisation